Lupus & antiphospholipid syndrome
Cost-related prescription non-adherence and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance program
Main finding · Current SLE disease activity (SLAQ), adjustedResult — go to the resultΒ coeff 2.7 95% CI 1.3–4.1Authors' conclusion
Patients with SLE who reported CRNA in the previous 12 months had significantly worse self-reported current disease activity and damage scores compared to those not reporting CRNA.
Study context
- Population
- Patients meeting systemic lupus erythematosus (SLE) criteria in the population-based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort, Michigan; interviews 2014–2015430 (93.1%) female
- Participants
- 462 patients
- Exposure
- Cost-related non-adherence (CRNA) vs no CRNA
- CRNAn = 100
- Outcome
- SLE disease activity (SLAQ) and damage (LDIQ)
Methodological detailspopulation-based cohort (MILES), structured interviews, multivariable linear regression
- Population-based cohort (MILES)
- Structured interviews
- Multivariable linear regression
Main finding
Current SLE disease activity (SLAQ), adjusted
Β coeff
2.7
95% CI 1.3–4.1
P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | β coeff (95% CI) | P value |
|---|---|---|
| SLE damage (LDIQ), adjustedAdjusted for covariates | 1.4 (0.5–2.4) | P = 0.003 |
Other factors independently associated with higher SLAQ and LDIQ
- Race, health insurance status and fulfilling Fibromyalgia (FM) Survey Criteria associated with higher (worse) SLAQ and LDIQ; female sex with higher SLAQ
Original publication
Cost-related prescription non-adherence and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance program. Lupus. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →